Abstract |
Paraneoplastic syndromes denote rare but notable phenomena caused by the tumour mediated release of bioactive substances. Peptide and non- peptide hormone causes are explored with a particular focus on pathogenesis, symptoms, diagnosis and treatment. Early detection and management of paraneoplastic syndromes can improve morbidly and mortality; definitive treatment remains effective surgical or anti-tumour therapies. Pituitary autoimmunity may provide a novel presentation of paraneoplastic syndromes for which further research is warranted.
|
Authors | Michael C Onyema, Eftychia E Drakou, Georgios K Dimitriadis |
Journal | Best practice & research. Clinical endocrinology & metabolism
(Best Pract Res Clin Endocrinol Metab)
Vol. 36
Issue 3
Pg. 101621
(05 2022)
ISSN: 1878-1594 [Electronic] Netherlands |
PMID | 35153144
(Publication Type: Case Reports, Journal Article, Review)
|
Copyright | Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved. |
Topics |
- Endocrine System Diseases
(complications, diagnosis)
- Humans
- Neoplasms
- Paraneoplastic Endocrine Syndromes
(diagnosis, etiology, therapy)
- Paraneoplastic Syndromes
(complications, etiology)
- Pituitary Diseases
(complications)
|